GSK receives positive CHMP opinion for REVOLADETM in thrombocytopenia associated with chronic hepatitis C infection

Today, GlaxoSmithKline plc (GSK) announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for REVOLADETM (eltrombopag).
Source: GSK news - Category: Pharmaceuticals Source Type: news